4DMedical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

4DMedical wird ein jährliches Gewinn- und Umsatzwachstum von 46% bzw. 66.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -10.5% betragen.

Wichtige Informationen

46.0%

Wachstumsrate der Gewinne

55.3%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	20.8%
Wachstumsrate der Einnahmen	66.8%
Zukünftige Eigenkapitalrendite	-10.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Sep 21

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

May 08

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

Feb 20

Gewinn- und Umsatzwachstumsprognosen

ASX:4DX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	57	-8	-6	-3	3
6/30/2026	36	-14	-12	-9	3
6/30/2025	13	-32	-29	-27	3
6/30/2024	4	-36	-32	-31	N/A
3/31/2024	2	-33	-33	-32	N/A
12/31/2023	1	-31	-34	-32	N/A
9/30/2023	1	-31	-29	-28	N/A
6/30/2023	1	-31	-24	-23	N/A
3/31/2023	1	-30	-19	-18	N/A
12/31/2022	1	-28	-15	-13	N/A
9/30/2022	1	-26	-22	-19	N/A
6/30/2022	1	-25	-29	-25	N/A
3/31/2022	1	-23	-28	-24	N/A
12/31/2021	0	-21	-26	-23	N/A
9/30/2021	0	-21	-21	-19	N/A
6/30/2021	0	-21	-15	-15	N/A
3/31/2021	0	-26	-16	-15	N/A
12/31/2020	0	-30	-16	-15	N/A
9/30/2020	1	-26	-12	-11	N/A
6/30/2020	1	-22	-9	-8	N/A
3/31/2020	2	-16	-8	-7	N/A
12/31/2019	2	-9	-7	-6	N/A
9/30/2019	1	-8	-7	-6	N/A
6/30/2019	1	-6	-7	-6	N/A
6/30/2018	1	-4	-5	-3	N/A
6/30/2017	1	-4	N/A	-2	N/A
12/31/2015	0	-1	N/A	-1	N/A
12/31/2014	0	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4DX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 4DX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 4DX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 4DXDie Einnahmen des Unternehmens (66.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.7% pro Jahr).

Hohe Wachstumseinnahmen: 4DXDie Einnahmen des Unternehmens (66.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4DX wird voraussichtlich in 3 Jahren unrentabel sein.

4DMedical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 36%

Consensus revenue estimates fall by 20%

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

4DMedical Limited, Annual General Meeting, Nov 20, 2024

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Consensus revenue estimates fall by 36%

Full year 2024 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

Consensus revenue estimates fall by 20%

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.

4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software

Forecast to breakeven in 2026

New major risk - Share price stability

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

New minor risk - Market cap size

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

4DMedical Limited, Annual General Meeting, Nov 02, 2023

Forecast to breakeven in 2026

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Consensus revenue estimates increase by 55%

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4Dmedical Unveils XV Scanner

Price target increased to AU$1.33

4DMedical Limited Releases CT LVAS in Australia

American Medical Association Current Procedural Terminology Editorial Panel Accepts 4Dmedical's Application for the Addition of A New Category III CPT Code

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

4DMedical Limited, Annual General Meeting, Nov 03, 2022

4DMedical Limited Updates Vanderblit 'Burn Pit' Trial Hits Primary Endpoint

Consensus forecasts updated

Full year 2022 earnings: Revenues miss analyst expectations

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

4Dmedical Limited Announces CFO Changes

High number of new directors

4DMedical Limited Appoints John Livingston as Role of Senior Strategist and Executive Director

4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference

High number of new directors

Price target decreased to AU$1.50

Price target decreased to AU$1.50

4DMedical Limited Announces Executive Changes

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

High number of new directors

4DMedical Limited Announces First Commercial Scans with I-MED to Commence in December

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Full year 2021 earnings released

4D Medical Announces Undertaking Clinical Trial At the John Hopkins School of Medicine in Baltimore, USA

4DMedical Limited Commences XV LVAS Clinical Trial at Johns Hopkins School of Medicine, US

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

4DMedical Limited Commences Patient Recruitment for VQ Trial

New 90-day low: AU$1.65

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.04 loss in 1H 2020)

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

4DMedical Limited Appoints Mr. Craige Pendleton-Browne as Chief Information Officer

New 90-day low: AU$2.07

4DMedical Limited Provides Update on Its First Clinical Pilot for XV Lung Ventilation Analysis Software

4DMedical Limited Completes First Commercial Scan in Australia

4Dmedical Limited Partners with University of Miami Health System to Establish the Functional Lung Imaging Research Program

4Dmedical Limited Receives TGA Approval for XV Lung Ventilation Analysis Software (XV LVAS)